although both shorter and longer linkers have been reported, it still seems empirical and optimization is required for each pair of ligase and target protein, since it is likely that optimal linker identity will vary for different proteins targeted
Friedreich ataxia: current status and future prospects
Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon
Pancreatitis was reported as a serious side effect of Ozempic during clinical trials of the medication
IV infusions must be administered in a clinical setting, typically over two to four hours per session
If symptoms are persistent or moderate in severity, a short course (typically two to four weeks) of a proton pump inhibitor (PPI) such as omeprazole available over the counter in the UK may be considered, ideally following discussion with a pharmacist or GP